USFDA approves neurological drug from Zydus
Advertisement
With 160 ANDAs pending by the Zydus group, this is the 100th approval on the list
Zydus Cadila has received the green signal to market the Pyridostigmine Bromide Tablets USP, 60 mg. The approval comes from the US drug regulator, USFDA and is a milestone achievement for the company, as it strikes one more new drug approval from the total application of 260 filed till date.
This lucky number of 100th drug application (from over 260 ANDAs since the commencement of the filing process in FY 2003-04) approval, is estimated to generate a whopping sale of $27.9 million as per IMS. The drug in action is used for treatment of various neurological disorders
Zydus Cadila has received the green signal to market the Pyridostigmine Bromide Tablets USP, 60 mg. The approval comes from the US drug regulator, USFDA and is a milestone achievement for the company, as it strikes one more new drug approval from the total application of 260 filed till date.
This lucky number of 100th drug application (from over 260 ANDAs since the commencement of the filing process in FY 2003-04) approval, is estimated to generate a whopping sale of $27.9 million as per IMS. The drug in action is used for treatment of various neurological disorders
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.